HFpEF Treatment in 2026: New Therapeutic Pillars
HFpEF finally has its own therapeutic pillars. A 2026 review of SGLT2 inhibitors, finerenone (FINEARTS-HF), GLP-1 RAs (STEP-HFpEF, SUMMIT), and emerging combination strategies for heart failure with preserved ejection fraction.
GLP-1 Receptor Agonists and Cardiovascular Outcomes in 2026
A comprehensive review of GLP-1 receptor agonists and their cardiovascular benefits beyond weight management, including MACE reduction, heart failure outcomes, and implications for clinical practice in 2026.